Scott Stroup, MD, MPH University of North Carolina at Chapel Hill

Slides:



Advertisements
Similar presentations
Regulatory Clinical Trials Clinical Trials. Clinical Trials Definition: research studies to find ways to improve health Definition: research studies to.
Advertisements

Treating Schizophrenia in Low And Middle Income (LAMI) Countries: Challenges and opportunities Treating Schizophrenia in Low And Middle Income (LAMI) Countries:
New England Journal of Medicine October 18;367: Relapse Risk after Discontinuation of Risperidone in Alzheimer’s disease Molly Moncrieff.
1 Timing and Duration of Relapse Prevention Trials in Psychiatric New Drug Development David Michelson, M.D. Executive Director, Neuroscience Medical Research.
Intro to Psychopharmacology Caitlin Stork, MD. Besides dopamine blockade... ReceptorEffect of Blockade Acetylcholine (muscarinic; M1) Anticholinergic.
Journal Club Alcohol, Other Drugs, and Health: Current Evidence January–February 2011.
Journal Club Alcohol, Other Drugs, and Health: Current Evidence May–June 2009.
Impact of Side Effects of Antipsychotics on Attitude and Adherence to Treatment among Adult Psychiatric Outpatients at Mathari Hospital in Kenya Defense.
Decision Analysis as a Basis for Estimating Cost- Effectiveness: The Experience of the National Institute for Health and Clinical Excellence in the UK.
Are Benzodiazepines Still the Medication of Choice for Patients With Panic Disorder With or Without Agoraphobia? By : s.bruce, PhD et al (Am J Psychiatry.
Dexmedetomidine vs Midazolam for Sedation of Critically Ill Patients A Randomized Trial Journal Club 09/01/11 JAMA, February 4, 2009—Vol 301, No
Value of Information Calculations to Inform and Prioritize Clinical Research Investments David Meltzer MD, PhD The University of Chicago.
1 Informative Studies of New Therapeutic Agents in Major Depression, GAD & Panic W Z Potter, M.D., PhD. Merck Research Laboratories.
Effectiveness of Antipsychotic Drugs in Patients with Chronic Schizophrenia: Efficacy and Safety Outcomes of the CATIE Trial Ira D. Glick, MD Stanford.
The Clinical Antipsychotic Trials of Intervention Effectiveness Trial
Implementing NICE guidance
Frequency and type of adverse events associated with treating women with trauma in community substance abuse treatment programs T. KIlleen 1, C. Brown.
De-diffusion of medical treatments: Atypical antipsychotics the treatment of mental illness Robert Rosenheck MD Yale Medical School.
1 Just The Facts Ma’am Dementia Care & Anti-Psychotics Just The Facts Ma’am December 17, 2012 Ronald A. Savrin, MD, MBA, FACS Medical Director, Ohio KePRO.
Evaluation and Intervention for the Persistently Ill Schizophrenic Person S. Charles Schulz, M.D. Professor and Head, Department of Psychiatry
Next-Generation Strategies for the Therapeutic Management of Schizophrenia Diana O. Perkins, MD, MPH Professor, Department of Psychiatry Medical Director.
Systematic Reviews.
Study design P.Olliaro Nov04. Study designs: observational vs. experimental studies What happened?  Case-control study What’s happening?  Cross-sectional.
Effect of Depression on Smoking Cessation Outcomes Sonne SC 1, Nunes EV 2, Jiang H 2, Gan W 2, Tyson C 1, Reid MS 3 1 Medical University of South Carolina,
Clinical Trial Designs An Overview. Identify: condition(s) of interest, intended population, planned treatment protocols Recruitment of volunteers: volunteers.
DRAFT SLIDES FOR NDA ADVISORY COMMITTEE PRESENATIONS.
1 Governor’s Office of Health Policy and Finance MaineCare Pharmacy Initiatives.
Use of Atypical Antipsychotic Drugs by Children and Adolescents in the United States: A Retrospective Cohort Study Lesley H. Curtis, PhD Center for Clinical.
Using Recent Research to Improve the Cost-Effectiveness of VA Antipsychotic Formulary Policy Robert Rosenheck MD Michael Sernyak MD New England MIRECC.
Risk of Serious Cardiac Events in Older Adults Using Antipsychotic Agents Sandhya Mehta, MS; Hua Chen, MD, PhD; Michael Johnson, PhD; and Rajender R. Aparasu,
Pharmacotherapy in Psychotic Disorders. Antipsychotic drugs Treat the symptoms of the disorder Do not cure schizophrenia Include two major classes: –
Barriers to achieve remission and recovery in schizophrenia Prof Köksal Alptekin MD Dept of Psychiatry Dokuz Eylül University School of Medicine İzmir-TURKEY.
Secondary Translation: Completing the process to Improving Health Daniel E. Ford, MD, MPH Vice Dean Johns Hopkins School of Medicine Introduction to Clinical.
Raymond F. Anton, MD for The COMBINE Study Research Group
The COMBINE Study: Design and Methodology Stephanie S. O’Malley, Ph.D. for The COMBINE Study Research Group JAMA Vol. 295, , 2006 (May 3 rd.
Treatment of Schizophrenia THE DEBATE OF THE YEAR! EFFICACY vs. TOLERABILITY: WHICH TRUMPS? POINT- COUNTERPOINT.
CAFE TRIAL Ron Beasley, PharmD Candidate Preceptor: Soheyla Mahdavian, PharmD 1.
Ron Beasley, PharmD Candidate Preceptor: Soheyla Mahdavian, PharmD
Use of Antipsychotic Drugs in Dementia Josepha A. Cheong, MD University of Florida Departments of Psychiatry and Neurology Chief, Division of Geriatric.
They deserve personalized treatment Your patients are unique.
MIAMI: MIRECC Initiative on Antipsychotic Management Improvement Metabolic Monitoring and Management of Antipsychotic Medication.
EBM --- Journal Reading Presenter :呂宥達 Date : 2005/10/27.
Teresa Hudson, PharmD Center for Mental Healthcare and Outcomes Research South Central Mental Illness Research Education and Clinical Center.
Changes in Antipsychotic Pharmacotherapy and Healthcare Costs Following a New Diagnosis of Diabetes among Patients with Schizophrenia Douglas L. Leslie,
Long-Term Efficacy Data for Psychiatric Drugs Thomas Laughren, M.D. Director, Division of Psychiatry Products (HFD-130) PDAC Meeting (Oct 25, 2005)
1 International Society for CNS Clinical Trials and Methodology FDA Advisory Committee Meeting Proposed Requirement for Long-Term Data to Support Initial.
Prescribing in Dementia. Plan What to prescribe? When to prescribe? How to review? Who to review?
WPA Atypical or Second Generation Neuroleptics. WPA Period 4: BPRS Total Score During Double-Blind Period.
First-Generation Versus Second- Generation Antipsychotics in Adults: Comparative Effectiveness Prepared for: Agency for Healthcare Research and Quality.
Treatment for Early onset Schizophrenia Treatment for Early onset Schizophrenia Chia-Yi Christian Hospital Department of psychiatry Hou, Yuh-Ming M.D.
Randomized Controlled CTN Trial of OROS-MPH + CBT in Adolescents with ADHD and Substance Use Disorders Paula Riggs, M.D., Theresa Winhusen, PhD., Jeff.
Antipsychotic Medications: Prevalence of Inappropriate Use, Polypharmacy, and Non-Adherence Nancy G. Pham, PharmD; Lisa Le, MS; Karen M. Stockl, PharmD;
EVALUATING THE EFFECTIVENESS OF THE AGS UPDATED 2012 BEERS CRITERIA AS AN EDUCATIONAL TOOL IN A FAMILY MEDICINE RESIDENCY TRAINING PROGRAM Eseoghene Abokede.
思覺失調症 精神科主治醫師 游佩琳.
PRAGMATIC Study Designs: Elderly Cancer Trials
Pharmacological management of delirium
Number Needed To Treat (NNT)
Module 3 Indications for Antipsychotics Bipolar Disorder
Treatment with rosuvastatin for severe dyslipidaemia in patients with schizophrenia and schizoaffective disorder M De Hert1, D Kalnicka1, R van Winkel1,
Seema Jain1, Rebecca Andridge2, Jessica Hellings3
CLINICAL PROTOCOL DEVELOPMENT
Neal B, et al. Diabetes Care 2015;38:403–411
Randomized Trials: A Brief Overview
Antipsychotics and Diabetes
Antipsychotic Agents and Their Use in Schizophrenia
Copyright Notice This presentation is copyrighted by the Psychopharmacology Institute. Subscribers can download it and use it for professional use. The.
Schizophrenia Consult
Antipsychotics: chemistry and pharmacokinetics
Insomnia pharmacotherapy: Off-label antipsychotics
Module 3 Indications for Antipsychotics Bipolar Disorder
Presentation transcript:

Scott Stroup, MD, MPH University of North Carolina at Chapel Hill Comparative Effectiveness of Antipsychotic Drugs in Patients with Chronic Schizophrenia: Findings to Date from the NIMH-CATIE Schizophrenia Trial Scott Stroup, MD, MPH University of North Carolina at Chapel Hill

Research program to evaluate the effectiveness of antipsychotic medications for schizophrenia and Alzheimer’s disease in “real-world” settings

Determinants of drug effectiveness Staying on the drug is critical Efficacy Tolerability Decision to stay on the drug Clinician Input Patient Input

The approach to extrapyramidal side effects is a key methodologic issue in comparative studies of first- and second-generation antipsychotic drugs.

New Antipsychotics vs Haloperidol ‘Pooled’ Data on use of anticholinergics Use of Anticholinergic Medication Olanzapine pooled r=.35*; n=2694 (3 studies) Quetiapine pooled r=.38*; n=758 Risperidone pooled r=.12*; n=1938 (7 studies) Greater Use Lesser Use The newer atypicals are associated with less EPS than haloperidol -0.4 -0.3 0.2 -0.1 0 0.1 0.2 0.3 0.4 0.5 r (95% CI) *Statistically significant. Modified from Leucht S, et al. Schizophr Res. 1999;35:51-68.

Atypical antipsychotics in the treatment of schizophrenia: meta­regression analysis (Geddes et al for the National Schizophrenia National (UK) Schizophrenia Guideline Development Group 2000) Result: When the dose was <12 mg/day of haloperidol (or equivalent), atypical antipsychotics had no benefits in terms of efficacy or overall tolerability, but they still caused fewer extrapyramidal side effects. Conclusion: There is no clear evidence that atypicals are more effective or better tolerated than conventional antipsychotics. Therefore, conventional antipsychotics should usually be used in the initial treatment of schizophrenia Geddes and colleagues looked at symptoms, side effects, and rate of drop out and came up with the conclusions on the slide. Of course, this conclusion is drawn in the UK, which has a very different health system than the U.S. But when stewardship of public dollars are concerned people seem to take a different view of whether the marginal benefits of atypicals justify the costs and trade-offs required due to potentially huge expenditures. An accompanying editorial from Canada, in a setting where the costs of drugs are paid for through public funds, reported that patients almost always choose atypicals when given the opportunity. Geddes was highly criticized by the drug companies and by some consumer advocates.

Effectiveness and cost of olanzapine and haloperidol: A randomized clinical trial Rosenheck et al. JAMA 2003 All patients assigned haloperidol also received benztropine to minimize EPS.

Olanzapine vs. Haloperidol; Rosenheck et al, 2003 Figure 2. Symptom outcomes (PANSS total scores) among patients assigned to clozapine or standard antipsychotic treatment , stratified by whether they continued to take clozapine or a standard medication (completers), or crossed over to the other treatment (crossovers). Note: Crossovers from clozapine to standard treatment occurred at 3.8 + 3.2 months (median 2.5 months). Crossovers from haloperidol to clozapine occurred at 5.5 + 3.0 months (median 4.8 months). Mixed model analysis: ns

Mixed model analysis: ns Olz. N: 159 121 108 93 90 92 Hal. N: 150 115 105 94 83 85

Side Effects of Atypical Antipsychotics: Shift in Risk Perception Prior Safety Concerns Current Safety Concerns Diabetes Neurologic Side Effects Weight Gain EPS + TD Hyper Glycemia CVD Insulin Resistance Side Effects of Atypical Antipsychotics: Shift in Risk Perception Weight Gain Insulin Resistance Hyper- lipidemia EPS QTc Dyslipidemia CVD QTc Hyper- glycemia

Chronic Schizophrenia: Key Recommendations of the Schizophrenia Patient Outcomes Research Team (PORT) No clear statement of preference of SGAs over FGAs in acute or maintenance treatment Clozapine the treatment of choice for treatment-refractory positive symptoms; clozapine also recommended for hostility and suicidality Lehman AF et al. Schizophr Bull. 2004;30:193-217.

Rationale for CATIE Published studies have significant limitations: Predominantly short-term studies designed for regulatory approval and labeling language Comparators are either placebo or a single active agent (usually haloperidol) Results have limited generalizability because they lack representative patient samples, clinical settings and treatment conditions Existing studies do not address critical clinical and policy questions Sponsored by pharmaceutical companies Clinical experience and case reports are not an adequate substitute for data Existing data largely from studies sponsored by drug companies for regulatory and marketing purposes- these typically focus on short-term efficacy and involve carefully selected patients who have no concurrent medical illnesses or substance use disorders and are conducted in rarified settings, like inpatient research units where medication compliance is ensured, that do not resemble usual practice. In other words, there is little data to inform us about the real-world effectiveness of these trials.

Practical Clinical Trials Designed to answer questions faced by clinicians and policy makers Compare clinically relevant alternative interventions Include a representative population of study participants Conduct studies at representative practice settings Simulate actual treatment conditions Collect data on a broad range of health outcomes that are clinically meaningful Tunis et al JAMA 2003, March et al AJP 2005

How Does a Practical Clinical Trial Differ from a Traditional Clinical Trial? Traditional Clinical Trials Practical Clinical Trials Population Exclusive Inclusive Setting Recruitment relies on patients coming to academic health centers. Recruitment relies on community practice settings, including private practices and state facilities. Design Treatment vs. Placebo Treatment vs. Treatment Duration Weeks Months Outcome Symptoms (efficacy) Symptoms and Function (effectiveness) Courtesy Tom Insel, MD

CATIE: Broad Inclusion & Minimal Exclusion Criteria DSM-IV schizophrenia, 18-65 years old Not first-episode or treatment resistant Concomitant medications, medical illnesses, substance use disorders allowed Conducted at 57 geographically, demographically and organizationally diverse sites In order to enroll a broad array of patients representing those who are actually seen in clinics, we developed minimal inclusion and exclusion criteria: Stroup TS et al. Schizophr Bull. 2003;29:15-31.

Primary Questions Addressed by CATIE Schizophrenia Trial How do the second generation antipsychotics compare with a representative first generation antipsychotic? What is the comparative effectiveness of the second generation antipsychotic drugs? Are the second generation antipsychotics cost-effective? Stroup TS et al. Schizophr Bull. 2003;29:15-31.

CATIE Schizophrenia Trial: Overview Participants 1460 people with schizophrenia Trial duration Subjects participate for 18 months Design Practical trial that is a hybrid of efficacy and effectiveness trial designs Stroup TS et al. Schizophr Bull. 2003;29:15-31.

CATIE Schizophrenia Trial Design Phase 1* R OLANZAPINE QUETIAPINE RISPERIDONE ZIPRASIDONE PERPHENAZINE Double-blind, random treatment assignment. Phase 2 Phase 3 Participants who discontinue Phase 1 choose either the clozapine or the ziprasidone randomization pathways Participants who discontinue Phase 2 choose one of the following open-label treatments ARIPIPRAZOLE CLOZAPINE CLOZAPINE (open-label) FLUPHENAZINE DECANOATE 1460 patients with SCZ Comorbidity Other meds R OLANZAPINE, QUETIAPINE or RISPERIDONE OLANZAPINE PERPHENAZINE ZIPRASIDONE QUETIAPINE R OLANZAPINE, QUETIAPINE or RISPERIDONE RISPERIDONE ZIPRASIDONE No one assigned to same drug as in Phase 1 2 of the antipsychotics above *Phase 1A: participants with TD (N=231) do not get randomized to perphenazine; phase 1B: participants who fail perphenazine will be randomized to an atypical (olanzapine, quetiapine, or risperidone) before eligibility for phase 2. Stroup TS et al. Schizophr Bull. 2003;29:15-31.

Primary Effectiveness Measure: All-Cause Treatment Discontinuation Efficacy Tolerability All-Cause Discontinuation Clinician Input Patient Input Stroup TS et al. Schizophr Bull. 2003;29:15-31.

Stroup TS et al. Schizophr Bull. 2003;29:15-31. Secondary Outcomes Symptom measures Safety Service use and costs Neurocognition Treatment adherence Comorbidity Quality of Life Substance use Violence Psychiatric studies usually have “cumbersome and lengthy follow-up interviews.” We are doing perhaps more of these than is desirable because of our and our funding agency’s desire to use this effort to obtain lots of data and to have available some evidence of our primary outcome’s validity. For efficacy we are using the usual rating scales. We have familiar monthly ratings of side effects and questions about other possible adverse events. We have a neurocognitive battery. We have multiple measures of treatment adherence. And we have a monthly interview about service use that will be used in cost-effectiveness and cost-benefit analyses. Stroup TS et al. Schizophr Bull. 2003;29:15-31.

CATIE Phase 1: Double-Blinded and Randomized Olanzapine 7.5–30 mg/day Perphenazine 8–32 mg/day 1460 Patients with Schizophrenia Randomized Quetiapine 200–800 mg/day Risperidone 1.5–6 mg/day Ziprasidone 40–160 mg/day * Persons with TD not assigned to perphenazine * Ziprasidone added after 40% sample enrolled Stroup TS et al. Schizophr Bull. 2003;29:15-31.

Demographic & Clinical Characteristics Insert Edited Table 1

Prevalence of Metabolic Syndrome in CATIE Schizophrenia Study Participants at Baseline vs. the General Adult Population (NHANES Data) CATIE (N = 689) * NHANES (N = 687) * CATIE = Clinical Antipsychotic Trials in Intervention Effectiveness; NHANES = National Health and Nutrition Examination Survey. *P = 0.0001 CATIE vs NHANES. McEvoy et al. Schizophrenia Research 2005

Substance Use in CATIE Subjects (Alcohol and Illicit Drugs) Source of data: Marvin Swartz, MD; unpublished data.

Phase I Randomization and Treatment Intent-to-treat (ITT) patients received at least one dose of study medication. Dose and efficacy assessments are reported for the ITT patients. Safety assessments are reported for all randomized patients.

Time to Discontinuation for Any Reason Overall p-value = 0.004* P<0.001 for olanzapine vs quetiapine P=0.002 for olanzapine vs risperidone The Kaplan Meier median is the time by which half of the patients have discontinued The hazard ratio for olanzapine vs. quetiapine is 0.63: at any given time, patients on olanzapine are 63% less likely to discontinue treatment compared to patients on quetiapine. The Hazard ratio is from Cox proportional hazards regression, and is the ratio of the probability of discontinuing the phase at any timepoint for one treatment group vs. another.

Time to Discontinuation for Lack of Efficacy Overall p-value < 0.001* P<0.001 for olanzapine vs quetiapine, risperidone and perphenazine The Kaplan Meier 25th %ile is the time by which 25% of the patients have discontinued. The median can not be estimated due to low event rates. The hazard ratio for olanzapine vs. quetiapine is 0.41: at any given time, patients on olanzapine are 41% less likely to discontinue treatment for lack of efficacy compared to patients on quetiapine. The Hazard ratio is from Cox proportional hazards regression, and is the ratio of the probability of discontinuing the phase at any timepoint for one treatment group vs. another.

Time to Discontinuation for Intolerability Overall p-value = 0.054 Kaplan Meier medians and 25th %ile can not be estimated due to low event rates The hazard ratio for risperidone vs. olanzapine is 0.62: at any given time, patients on risperidone are 62% less likely to discontinue treatment for intolerability compared to patients on olanzapine. This difference is not significant since the overall p-value was not less than 0.05. The Hazard ratio is from Cox proportional hazards regression, and is the ratio of the probability of discontinuing the phase at any timepoint for one treatment group vs. another.

Reasons for Discontinuation Due to Intolerability All Randomized Patients Discontinued for Intolerability 15% Weight/Metabolic 4% Extrapyramidal 4% Sedation 2% Other 5%

PANSS Total Score P=0.001 for time-by-treatment interaction P=0.065 for ziprasidone cohort Interaction of time × treatment indicates significant variation in treatment effects over time. Improvement was initially greatest with olanzapine but its advantage diminished over time. The number of patients declines over assessment times. Least -square mean estimates are from a mixed model, which assumes that data are missing at random. Values at later time points are based on the observed data for continuing patients as well as  estimated data for discontinued patients.  

PANSS Positive Score P=0.004 for time-by-treatment interaction P=0.346 for ziprasidone cohort Interaction of time × treatment indicates significant variation in treatment effects over time. The number of patients declines over assessment times. Least -square mean estimates are from a mixed model, which assumes that data are missing at random. Values at later time points are based on the observed data for continuing patients as well as  estimated data for discontinued patients.  

PANSS Negative Score P=0.177 for time-by-treatment interaction P=0.019 for ziprasidone cohort The number of patients declines over assessment times. Least -square mean estimates are from a mixed model, which assumes that data are missing at random. Values at later time points are based on the observed data for continuing patients as well as  estimated data for discontinued patients.  

Hospitalizations for Exacerbation of Schizophrenia

Treatment-Emergent Adverse Events

Treatment-Emergent Neurologic Effects AIMS percentages exclude TD patients. Barnes and Simpson-Angus percentages in NEJM did not exclude TD patients

Weight change from Baseline to Last Observation

Laboratory Chemistry: Change from Baseline to Average of Two Highest Values patients were instructed to fast, nonfasting results were not excluded Exposure-adjusted means are the estimated mean values that we would see at the average treatment duration across all groups (8.3 months). They are least squares means from an ANCOVA model adjusting for treatment duration.

Reasons for Discontinuation Due to Intolerability All Randomized Patients FYI: the percentages of patients discontinued for intolerability differ slightly between this slide and the previous one because this slide is based on all randomized patients, and the previous slide is limited to ITT patients who took at least one dose of study medication.

Key Messages CATIE provides important new information on antipsychotic drugs that should greatly assist doctors and patients in making individualized treatment choices. Overall, all the medications were comparably effective but were associated with high rates of discontinuation due to intolerable side effects, failure to adequately control symptoms, or other reasons.

Key Messages Olanzapine was somewhat more efficacious than the other drugs but also was associated with significant weight gain and metabolic changes. The older medication perphenazine generally performed as well as the newer medications. The older medication was as well tolerated as the newer drugs and was as effective as three of the newer medications. Contrary to expectations, EPS was not seen more frequently with perphenazine than with the newer drugs.

Key Messages Treatments for persons with schizophrenia must be individualized. Doctors and patients must carefully evaluate the tradeoffs between efficacy and side effects in choosing an appropriate medication. What works for one person may not work for another.

Some early reactions

Washington Post New Antipsychotic Drugs Criticized Federal Study Finds No Benefit Over Older, Cheaper Drug September 20, 2005; A01 New York Times Study Finds Little Advantage in New Schizophrenia Drugs September 20, 2005 F-1 The Wall Street Journal Generic Fares Well in Big Psychiatry Study: Newer Costlier Drugs Have Little Advantage for Schizophrenia September 20, 2005 D-1

Alliance for Human Research Protection 29 July 2005: “Next Phase in Psychiatry? Or, NIMH Effort to Rescue Bad Drugs” 20 September 2005: “Federal Study Finds No Benefit of New Antipsychotic Drugs”

“Psychiatry hasn’t advanced in thirty years!” Schizophrenia Anonymous-Durham is going retro to celebrate Halloween On 9/20, the researchers got their treat: the psychiatric patients got the trick. …while saving Medicaid money and adjusting to those vintage neuroleptics, here’s some music to get you in the mood: “Let’s twist again”

Tom Toles Sketch, Washington Post, September 23, 2005

FAQs Are the newer medications better than the older ones? Are the newer drugs all the same? Are the older drugs all the same? Do the results with perphenazine apply to the others?

FAQs Why were the discontinuation rates so high? Were the doses comparable? Was the study long enough to make comparisons regarding tardive dyskinesia?

FAQs Should everyone be switched to a cheaper drug? Should we keep everything on the formulary? Why not start with the cheapest drugs?

FAQs Do we know what to do when someone doesn’t do well on one medication?

CATIE results still to come Cost-effectiveness evaluation Phase 2 studies: Efficacy pathway: clozapine vs. a second atypical Tolerability pathway: ziprasidone vs. a second Neurocognition Substance use, violence

Thank you.